UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Haematologica (Roma), 2012-04, Vol.97 (4), p.579-585

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity

Journal of clinical oncology, 2005-05, Vol.23 (15), p.3404-3411

2005

Link zum Volltext

Verfügbarkeit prüfen

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

Clinical cancer research, 2008-11, Vol.14 (21), p.7095-7101

2008

Link zum Volltext

Verfügbarkeit prüfen

Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion

Experimental hematology, 2001-02, Vol.29 (2), p.244-255

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

Blood, 2008-11, Vol.112 (11), p.2809-2809

2008

Link zum Volltext

Verfügbarkeit prüfen

Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads

Analytical biochemistry, 2005-12, Vol.347 (1), p.67-76

2005

Link zum Volltext

Verfügbarkeit prüfen

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype

Leukemia & lymphoma, 2014-07, Vol.55 (7), p.1523-1532

2014

Link zum Volltext

Verfügbarkeit prüfen

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Blood, 2009-08, Vol.114 (9), p.1736-1745

2009

Link zum Volltext

Verfügbarkeit prüfen

Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001

Blood, 2011-11, Vol.118 (21), p.2541-2541

2011

Link zum Volltext

Verfügbarkeit prüfen

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression

Blood, 2009-11, Vol.114 (22), p.1032-1032

2009

Link zum Volltext

Verfügbarkeit prüfen

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012)

Breast cancer research and treatment, 2010-01, Vol.119 (2), p.391-398

2010

Link zum Volltext

Verfügbarkeit prüfen

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)

Blood, 2009-11, Vol.114 (22), p.838-838

2009

Link zum Volltext

Verfügbarkeit prüfen

701 Detection of Minimal Residual Disease Following Induction Immunochemotherapy Predicts Progression Free Survival in Mantle Cell Lymphoma: Final Results of CALGB 59909

Clinical lymphoma, myeloma and leukemia, 2011-06, Vol.11, p.S130-S131

2011

Link zum Volltext

Verfügbarkeit prüfen

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia

Breast cancer research and treatment, 2010-01, Vol.119 (2), p.391

2010

Link zum Volltext

Verfügbarkeit prüfen

Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-alpha

The Journal of immunology (1950), 1997-03, Vol.158 (5), p.2390

1997

Link zum Volltext

Verfügbarkeit prüfen

Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples

International journal of oncology, 2006-05, Vol.28 (5), p.1099-1103

2006

Link zum Volltext

Verfügbarkeit prüfen

Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001

Blood, 2007-11, Vol.110 (11), p.2869-2869

2007

Link zum Volltext

Verfügbarkeit prüfen

The Histone Deacetylase Inhibitor (HDI) Depsipeptide Has Differential Activity in Core Binding Factor AML

Blood, 2006-11, Vol.108 (11), p.1956-1956

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia

Blood, 2006-11, Vol.108 (11), p.4923-4923

2006

Link zum Volltext

Verfügbarkeit prüfen

The IRS-pathway operates distinctively from the stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-α receptors

Blood, 1997-10, Vol.90 (7), p.2574-2582

1997

Link zum Volltext

Verfügbarkeit prüfen

Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710

Blood, 2006-11, Vol.108 (11), p.494-494

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(13)
Biological And Medical Sciences
(10)
Hematology
(8)
Medical Sciences
(8)
Middle Aged
(8)
Adult
(7)
Female
(7)
Oncology
(7)
Aged
(6)
Hematologic And Hematopoietic Diseases
(6)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(6)
Male
(6)
Treatment Outcome
(5)
Adolescent
(3)
Animals
(3)
Bcr-Abl
(3)
Cancer Research
(3)
Chromosome Aberrations
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012)

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)

701 Detection of Minimal Residual Disease Following Induction Immunochemotherapy Predicts Progression Free Survival in Mantle Cell Lymphoma: Final Results of CALGB 59909

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia

Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-alpha

Results of An International Study of Quantitative BCR/ABL Assays Using Defined RNA Samples

Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples

Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001

The Histone Deacetylase Inhibitor (HDI) Depsipeptide Has Differential Activity in Core Binding Factor AML

Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia

The IRS-pathway operates distinctively from the stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-α receptors

Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710

Suchergebnisse filtern